Corvus Pharmaceuticals Appoints Novo Nordisk Executive David Moore To Board Of Directors; Strengthening Leadership In Immunotherapy

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the appointment of David Moore, Executive Vice President of US Operations at Novo Nordisk A/S and President of Novo Nordisk Inc., to its Board of Directors. Moore brings nearly three decades of leadership experience in the pharmaceutical and biotechnology sectors, with expertise spanning commercial strategy, market access, business development, and investment.

“We are excited to welcome David to the Board,” said Richard A. Miller, M.D., chairman, president, and chief executive officer of Corvus. “His experience leading Novo’s U.S. business, including one of the most successful GLP-1 franchises that includes Ozempic, Wegovy and Rybelsus, along with his work in corporate strategy and business development, is anticipated to be an important strategic resource as we work to maximize the potential of our ITK inhibitor platform.”

Currently serving as Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., Moore has held numerous senior roles at the company, including EVP of Corporate Development and SVP of Commercial. His career also includes leadership positions as CEO of Lysovant Sciences (a Roivant company), President and Chief Commercial Officer of Cempra Pharmaceuticals, and a Partner at Gurnet Point Capital, a life science-focused private equity firm. Earlier in his career, he spent 14 years at Johnson & Johnson in sales, marketing, and business development. Moore holds an MBA in Marketing from Lehigh University and a BS in Biology from Towson University.

“Corvus has a compelling opportunity to develop ITK inhibition across cancer and immune diseases, leveraging a novel mechanism of action based on strong science with demonstrated potential in areas of significant patient need,” said Mr. Moore. “I am honored to join the Corvus Board of Directors and look forward to working with the team as the Company continues to advance its pipeline and growth opportunities.”

Corvus Pharmaceuticals is advancing a novel immunotherapy platform centered on ITK inhibition for cancer and immune disorders. Its lead candidate, soquelitinib, is an oral small molecule drug designed to selectively inhibit ITK. The company is also developing additional clinical-stage programs for multiple cancer indications, reinforcing its position as a pioneer in targeted immunotherapy innovation.